Skip to content

Gilead Recalls 55,000 Vials of Covid Drug Due to Glass Shards

  • Company has no reports of adverse events linked to recall
  • Glass particles could cause stroke or even death if injected
A vial of Veklury brand remdesivir anti-viral medication.
A vial of Veklury brand remdesivir anti-viral medication.Photographer: Nic Coury/Bloomberg

Gilead Sciences Inc. said it was recalling two lots of its Covid-19 drug remdesivir in the U.S. after receiving a complaint about glass particles in the vials that was confirmed by a company investigation.

The recall involves 55,000 vials of the drug, or enough to treat 11,000 hospitalized patients, company spokesman Chris Ridley said in an interview. He said the recall wouldn’t impact supply of the drug in the U.S. or the rest of the world, as the company has plenty of supply on hand.